The presence of tumor-infiltrating T lymphocytes can be increased when anti-programmed cell death protein 1 (anti-PD1) therapy is utilized by using drugs like Pembrolizumab, Nivolumab, and Cemiplimab [5,6,7]. This evidence concerns the gene PDCD1 and neoplasm.